CA3193947A1 - Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders - Google Patents
Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disordersInfo
- Publication number
- CA3193947A1 CA3193947A1 CA3193947A CA3193947A CA3193947A1 CA 3193947 A1 CA3193947 A1 CA 3193947A1 CA 3193947 A CA3193947 A CA 3193947A CA 3193947 A CA3193947 A CA 3193947A CA 3193947 A1 CA3193947 A1 CA 3193947A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- ampk
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
- C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2015585.9A GB202015585D0 (en) | 2020-10-01 | 2020-10-01 | New compounds |
| GB2015585.9 | 2020-10-01 | ||
| PCT/GB2021/052535 WO2022069894A1 (en) | 2020-10-01 | 2021-09-30 | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3193947A1 true CA3193947A1 (en) | 2022-04-07 |
Family
ID=73223766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3193947A Pending CA3193947A1 (en) | 2020-10-01 | 2021-09-30 | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230382930A1 (https=) |
| EP (1) | EP4222147B1 (https=) |
| JP (1) | JP7793614B2 (https=) |
| KR (1) | KR20230079163A (https=) |
| CN (1) | CN116368141B (https=) |
| AU (1) | AU2021352146A1 (https=) |
| CA (1) | CA3193947A1 (https=) |
| ES (1) | ES3018732T3 (https=) |
| GB (1) | GB202015585D0 (https=) |
| HU (1) | HUE071685T2 (https=) |
| MX (1) | MX2023003825A (https=) |
| PL (1) | PL4222147T3 (https=) |
| WO (1) | WO2022069894A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB202112529D0 (en) * | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| EP4600642A1 (en) * | 2022-10-05 | 2025-08-13 | Sawai Pharmaceutical Co., Ltd. | Method for selecting additive capable of inhibiting nitrosation reaction, and preparation prevented from generation of nitroso compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5982281B2 (ja) * | 2009-07-08 | 2016-08-31 | バルティック バイオ アーベー | 医薬として有用な化合物 |
| WO2013108026A1 (en) * | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| AU2018448511B2 (en) * | 2018-11-05 | 2025-07-03 | Betagenon Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
-
2020
- 2020-10-01 GB GBGB2015585.9A patent/GB202015585D0/en not_active Ceased
-
2021
- 2021-09-30 CN CN202180067894.4A patent/CN116368141B/zh active Active
- 2021-09-30 HU HUE21816508A patent/HUE071685T2/hu unknown
- 2021-09-30 WO PCT/GB2021/052535 patent/WO2022069894A1/en not_active Ceased
- 2021-09-30 EP EP21816508.2A patent/EP4222147B1/en active Active
- 2021-09-30 CA CA3193947A patent/CA3193947A1/en active Pending
- 2021-09-30 JP JP2023520459A patent/JP7793614B2/ja active Active
- 2021-09-30 ES ES21816508T patent/ES3018732T3/es active Active
- 2021-09-30 US US18/028,192 patent/US20230382930A1/en active Pending
- 2021-09-30 MX MX2023003825A patent/MX2023003825A/es unknown
- 2021-09-30 AU AU2021352146A patent/AU2021352146A1/en active Pending
- 2021-09-30 PL PL21816508.2T patent/PL4222147T3/pl unknown
- 2021-09-30 KR KR1020237014527A patent/KR20230079163A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE071685T2 (hu) | 2025-09-28 |
| JP7793614B2 (ja) | 2026-01-05 |
| CN116368141A (zh) | 2023-06-30 |
| ES3018732T3 (en) | 2025-05-19 |
| PL4222147T3 (pl) | 2025-06-09 |
| EP4222147C0 (en) | 2025-03-19 |
| JP2023543924A (ja) | 2023-10-18 |
| EP4222147A1 (en) | 2023-08-09 |
| AU2021352146A1 (en) | 2023-06-01 |
| MX2023003825A (es) | 2023-06-06 |
| EP4222147B1 (en) | 2025-03-19 |
| GB202015585D0 (en) | 2020-11-18 |
| WO2022069894A1 (en) | 2022-04-07 |
| KR20230079163A (ko) | 2023-06-05 |
| US20230382930A1 (en) | 2023-11-30 |
| CN116368141B (zh) | 2025-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4222147B1 (en) | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders | |
| US6706746B2 (en) | Thiazolidine-2,4-dione hydrochloride salt, pharmaceutical compositions thereof and treatment method therewith | |
| US10493158B2 (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| KR20050072809A (ko) | 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제 | |
| KR100716389B1 (ko) | Ｎ-히드록시－４－｛５－［４－（5－이소프로필－２－메틸－１,３－티아졸－4－일）페녹시］펜톡시｝벤즈아미딘 ２메탄술폰산염 | |
| KR102931162B1 (ko) | Glp-1 수용체 작용제 화합물의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
| AU2019360446A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| US20240082222A1 (en) | 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine | |
| US20250136563A1 (en) | Thiadiazolone derivatives useful as ampk activator | |
| EP4585593A1 (en) | Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof | |
| JP4548884B2 (ja) | ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン誘導体 | |
| HK40092998B (en) | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders | |
| HK40092998A (en) | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders | |
| WO2011124124A1 (zh) | 普拉格雷盐酸盐乙酸溶剂合物及其结晶和制备方法 | |
| CN111662239B (zh) | 1,2,4-三唑类化合物及其制法和药物用途 | |
| CN106432026A (zh) | 一类对糖尿病具有潜在治疗活性的化合物 | |
| WO2010098298A1 (ja) | 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物 | |
| WO2025099561A1 (en) | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| CA3215383A1 (en) | Pharmaceutical composition, and preparation method therefor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241007 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241007 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250109 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250305 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250305 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250305 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250305 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250310 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250310 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250310 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250310 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U107 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REFUND REQUEST RECEIVED Effective date: 20250317 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250916 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250916 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250925 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250925 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250925 |